Our experts can help you devise channel strategies and tailored solutions for access and uptake. And, we have market-leading reach into the sites of care where patients are being treated with biosimilars.

Our market-leading GPOs connect physicians and manufacturers for unrivaled purchasing power and education while our provider solutions offer tailored services for all sites of care. Plus, field reimbursement support helps practices navigate payment for these new products.

Our patient assistance program (PAP) models and adherence services are tailored to your product and patient needs and integrate seamlessly with our reimbursement and co-pay services.

In part one of a two-part series on insulin biosimilars, we’ll talk about what these new drugs could mean for the category.. 

COVID-19 changed the way physician practices and health systems interacted with patients. The pandemic has presented opportunities for greater engagement with customers who are building a strategy around adoption and cost savings.It has been a successful year, and 2021 looks just as promising. Sean McGowan anticipates new manufacturers and a second wave of products into existing biosimilar markets.

Biosimilars have the potential to reduce healthcare costs in the United States — but only if the market grows. Dr. Kashyap Patel, Medical Director at Carolina Blood and Cancer Care, provides perspective on how manufacturers can help deliver on the promise of cost savings by improving physician confidence in biosimilars.